central nervous system arteriovenous malformations
Conditions
Interventions
Case series:Oral thalidomide
Sponsors
Xuanwu Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with central nervous system AVMs who can not who can not benefit from current treatment methods. 2. Patients with central nervous system AVM who can refuse to receive current treatment methods. 3. Written informed consent to participate in the study prior to any study procedures.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating female patients. 2. Patients younger than 2 years old. 3. Patients who is preparing for pregnancy. 4. Patients with high risks of thrombogenesis (diabetes, severe infection, malignant tumor, history of thrombogenesis, deep vein catheterization and coagulation disorders) 5. Patients with severe comorbidities of cardiac, pulmonary, renal, liver, hematological diseases 6. Patients who is diagnosed as hereditary hemorrhagic telangiectasia (HHT).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| radiological change; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathological test;Neurological outcome;Biomarkers of the blood ;Averse effect; | — |
Countries
China
Contacts
Public ContactHongqi Zhang
Outcome results
None listed